Aytu BioPharma is a pharmaceutical company that develops and commercializes prescription medicines for central nervous system diseases and pediatric conditions. The company's flagship asset is EXXUA, an FDA-approved antidepressant for major depressive disorder that operates through a novel mechanism without sexual dysfunction side effects; it also markets two proprietary extended-release ADHD medications (Adzenys XR-ODT and Cotempla XR-ODT) and a pediatric portfolio including antihistamines and fluoride-based multivitamin supplements. The company generates revenue by selling these prescription products through pharmaceutical wholesalers, distributors, and pharmacies, while leveraging proprietary microparticle technology to differentiate its products and operating patient support programs to enhance access and market penetration in the large U.S. markets for depression, ADHD, allergies, and pediatric health.